seed
Stage
About
Adoram is a Swiss biotech spin-off from the University of Geneva developing small molecule allosteric modulators targeting adenosine receptors to create novel immunotherapies for solid tumors and immune-based diseases.
Explore Adoram's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.